Literature DB >> 11017144

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

S J Ries1, C H Brandts, A S Chung, C H Biederer, B C Hann, E M Lipner, F McCormick, W M Korn.   

Abstract

The adenovirus mutant dl1520 (ONYX-015) does not express the E1B-55K protein that binds and inactivates p53. This virus replicates in tumor cells with mutant p53, but not in normal cells with functional p53. Although intra-tumoral injection of dl1520 shows promising responses in patients with solid tumors, previous in vitro studies have not established a close correlation between p53 status and dl1520 replication. Here we identify loss of p14ARF as a mechanism that allows dl1520 replication in tumor cells retaining wild-type p53. We demonstrate that the re-introduction of p14ARF into tumor cells with wild-type p53 suppresses replication of dl1520 in a p53-dependent manner. Our study supports the therapeutic use of dl1520 in tumors with lesions within the p53 pathway other than mutation of p53.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11017144     DOI: 10.1038/80466

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  36 in total

Review 1.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Authors:  Sara J Edwards; Brett R Dix; Colleen J Myers; Deirdre Dobson-Le; Lily Huschtscha; Merilyn Hibma; Janice Royds; Antony W Braithwaite
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Antiviral action of the tumor suppressor ARF.

Authors:  María A García; Manuel Collado; César Muñoz-Fontela; Ander Matheu; Laura Marcos-Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

Review 5.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

6.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

Authors:  Charles M Rudin; Ezra E W Cohen; Vassiliki A Papadimitrakopoulou; Sol Silverman; Wendy Recant; Adel K El-Naggar; Kirsten Stenson; Scott M Lippman; Waun Ki Hong; Everett E Vokes
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

7.  MDM2 promotes ubiquitination and degradation of MDMX.

Authors:  Yu Pan; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

8.  A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.

Authors:  Neda Bagheri; Marisa Shiina; Douglas A Lauffenburger; W Michael Korn
Journal:  PLoS Comput Biol       Date:  2011-02-17       Impact factor: 4.475

Review 9.  ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Authors:  S Ries; W M Korn
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.